These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11185930)

  • 1. Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy.
    Pillai K; Kraya N
    Aust N Z J Psychiatry; 2000 Feb; 34(1):160-3. PubMed ID: 11185930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to 'Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy'.
    Paterson R
    Aust N Z J Psychiatry; 2000 Oct; 34(5):874-5. PubMed ID: 11037381
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder.
    Paterson R; Douglas C; Hallmayer J; Hagan M; Krupenia Z
    Aust N Z J Psychiatry; 1999 Aug; 33(4):494-502. PubMed ID: 10483843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
    Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamphetamine for obsessive-compulsive disorder.
    Woolley JB; Heyman I
    Am J Psychiatry; 2003 Jan; 160(1):183. PubMed ID: 12505824
    [No Abstract]   [Full Text] [Related]  

  • 11. [Life-threatening heart failure caused by ADHD medication. Five case reports described].
    Wikström G; Kvidal P; Hagström E
    Lakartidningen; 2012 Nov 7-13; 109(45):2016-8. PubMed ID: 23240309
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
    Findling RL; Ginsberg LD; Jain R; Gao J
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
    J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summer hours. One small intervention changed a child's world.
    Grossman VG
    Am J Nurs; 1999 Aug; 99(8):25. PubMed ID: 10456017
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Substitution of dexamethasone for dexamphetamine due to their written and spoken similarity].
    Hoppenbrouwers CJ; Mooren GC; van den Heuvel JJ; Op de Coul ME; van Trotsenburg PA
    Ned Tijdschr Geneeskd; 2010; 154():A1662. PubMed ID: 20858310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosis associated with prescribed dexamphetamine use.
    Spear J; Alderton D
    Aust N Z J Psychiatry; 2003 Jun; 37(3):383. PubMed ID: 12780481
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.